The in vitro activities of amphotericin B, miconazole, ketoconazole, 5-fluorocytosine, and potassium iodide (KI) were studied on human and wild-type isolates of Basidiobolus and Conidiobolus species. Of the antifungal agents tested, the imidazole derivatives, especially ketoconazole, were the most active against the agents of entomophthoromycosis. Transmission electron microscopy showed severe morphological alteration of Basidiobolus sp. exposed to 0.78 jig of ketoconazole per ml. The MIC and minimal fungicidal concentration of ketoconazole was often lowered in the presence of 10% fetal calf serum or antibiotic medium no. 3. Half of the Basidiobolus isolates and all Conidiobolus isolates were inhibited by amphotericin B at 0.39 ,ug/ml. None of the strains tested were inhibited or killed at maximum concentrations of 5-fluorocytosine and KI. The in vitro resistance of these fungi to KI at high concentrations suggests that the reported favorable treatment with KI may not be due to its direct effect on these fungi but rather to other, undefined factors in combination with KI. These data suggest that ketoconazole may be of use in the treatment of entomophthoromycosis, particularly in cases which are not responsive to KI.
lizard guts in Nigeria, and GA5 and Ti were obtained from a lizard gut and a toad, respectively, in Florida. Candida albicans with known susceptibility to various antifungal agents was used as the control organism.
Antifungal drugs. Amphotericin B was purchased from E. R. Squibb & Sons, Princeton, N.J. (NDC003-0437-30). 5-Fluorocytosine was kindly provided by Hoffmann-LaRoche, Inc., Nutley, N.J. (lot no. 134119). Miconazole (lot no. B02/ 1) and ketoconazole (lot no. C6401) were generously provided by Janssen Pharmaceutica, Inc., New Brunswick, N.J. Potassium iodide (KI) was purchased from Mallinckrodt, Inc., St. Louis, Mo. The solutions were prepared according to the instructions of the respective manufacturers.
Media. Unbuffered yeast-nitrogen base (YNB), antibiotic medium no. 3 (U.S. Food and Drug Administration), Sabouraud dextrose broth (SDB) and agar (SDA) (Difco Laboratories, Detroit, Mich.), and Eagle minimum essential medium (EMEM) supplemented with 10% fetal calf serum (GIBCO Laboratories, Grand Island, N.Y.) were utilized for the study.
Preparation of inocula. All isolates were grown on SDA at 30°C for 48 to 72 h to obtain young and actively growing cultures consisting of only mycelia and conidia without zygospores. Fungal scrapings were suspended in sterile saline and vortexed until an almost-uniform suspension of small fragments offungi was observed. From this, an adjusted fungal suspension of 104 to 105 cells per ml counted in a hemacytometer chamber was used as the source of inoculum.
Broth dilution method. The macro-broth dilution method of Shadomy and Espinel-Ingroff (19) was used in this study. To each dilution of antifungal agents ranging from 0.98 to 200.0 ,ug/ml, 0.1 ml of a fungal suspension was added. For KI, a maximum concentration of 30,000 ,ug/ml was used. These and the controls were incubated at 30°C for 48 h. The MIC was defined as a tube in which no visible growth, as compared with the control, could be seen. The minimal fungicidal concentration (MFC) was defined as a tube in which no growth occurred 48 h after being subcultured on a 414 YANGCO, OKAFOR, AND TESTRAKE Electron microscopy. Electron microscopy of a normal cell of Basidiobolus GAS is shown in Fig. 1A , and a cell exposed to 0.78 jig of ketoconazole per ml is shown in Fig. 1B . These latter cells are in a necrotic state in which no cell organelles are definable. (A) Control cell incubated for 48 h (magnification, x6,600); (B) fungal cell exposed to 0.78 p.g of ketoconazole per ml for 48 h (magnification, x6,600).
DISCUSSION
Our study showed that imidazole derivatives are active against the etiological agents of entomophthoromycosis. The highest MIC and MFC of miconazole for the majority of isolates was 3.12 Lg/ml, and the highest MIC and MFC of ketoconazole for all isolates was 1.56 ,ug/ml. These are within achievable therapeutic serum levels, which are 7 to 8 ,ug/ml after a 600-to 1,000-mg intravenous dose of miconazole (22) and 2 to 4 ,ug/ml after a 200-mg oral dose of ketoconazole (3) . Drug levels in serum of up to 50 ,ug/ml, if needed, may be achieved by higher doses of ketoconazole (3) . The (18) and entomophthoromycosis conidiobolae (11, (14) (15) (16) .
Maximum concentrations of 5-fluorocytosine and KI did not show any activity against the isolates tested. As with amphotericin B, 5-fluorocytosine has failed previously in the treatment of entomophthoromycosis (11) . The disparity between in vitro observations and the known in vivo activity of KI in entomophthoromycosis is of interest. Our in vitro results were comparable to those in earlier studies by Tio and deVries (25) , who felt that KI activity in this disease is not due to a direct effect on the fungus but rather to nonspecific action. A similar phenomenon has been observed with Sporothrix schenkii, in which initial in vitro studies failed to demonstrate any direct activity of KI against this fungus (5, 7) despite its high clinical efficacy in the treatment of sporotrichosis. Early investigators (5) suggest that KI stimulates the healing process in sporotrichosis. Others (20) have felt that molecular iodine may enhance phagocyte activity. Additional studies suggest that free or molecular iodine formed from the body may be fungicidal, whereas KI may be fungistatic (26, 27) . However, the in vitro iodide concentrations necessary to attain antifungal effects were much greater (-4 times) (26) than achievable levels in serum (ca. 50 pxg/ml), to explain a direct effect in vivo. Therefore, the exact mechanism of action of KI in sporotrichosis and entomophthoromycosis still remains to be elucidated.
This study suggests that the imidazole derivatives, particularly ketoconazole (an orally administered drug), may be effective in the treatment of entomophthoromycosis and may be considered a potential alternative therapy, especially in patients who failed to respond to KI therapy. However, clinical studies are needed to confirm our in vitro observations.
